Literature DB >> 12821494

In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

Margarita Garau1, Manolo Pereiro, Amalia del Palacio.   

Abstract

The in vitro activity of the new triazole albaconazole (UR-9825) in comparison with those of flucytosine, fluconazole, ketoconazole, itraconazole, and voriconazole against 70 strains of Malassezia spp. was determined by a microdilution method using a colorimetric indicator for metabolic activity. Albaconazole showed an in vitro profile similar to those of the different antifungals tested (MIC <or= 0.06 microg/ml for all the strains).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821494      PMCID： PMC161882          DOI： 10.1128/AAC.47.7.2342-2344.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Human infections due to Malassezia spp.

Authors:  M J Marcon; D A Powell
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.

Authors:  J Bartroli; E Turmo; M Algueró; E Boncompte; M L Vericat; L Conte; J Ramis; M Merlos; J García-Rafanell; J Forn
Journal:  J Med Chem       Date:  1998-05-21       Impact factor: 7.446

3.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  In vitro activity of systemic antifungal agents against Malassezia furfur.

Authors:  M J Marcon; D E Durrell; D A Powell; W J Buesching
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Molecular differentiation of seven Malassezia species.

Authors:  A K Gupta; Y Kohli; R C Summerbell
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

6.  In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine.

Authors:  A K Gupta; Y Kohli; A Li; J Faergemann; R C Summerbell
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

7.  In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

Authors:  J Capilla; M Ortoneda; F J Pastor; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

8.  In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.

Authors:  G Ramos; M Cuenca-Estrella; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

9.  Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit.

Authors:  S F Welbel; M M McNeil; A Pramanik; R Silberman; A D Oberle; G Midgley; S Crow; W R Jarvis
Journal:  Pediatr Infect Dis J       Date:  1994-02       Impact factor: 2.129

10.  Cluster of Malassezia furfur pulmonary infections in infants in a neonatal intensive-care unit.

Authors:  H M Richet; M M McNeil; M C Edwards; W R Jarvis
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948
View more
  18 in total

1.  In vitro amphotericin B susceptibility of Malassezia pachydermatis determined by the CLSI broth microdilution method and Etest using lipid-enriched media.

Authors:  Sergio Álvarez-Pérez; José L Blanco; Teresa Peláez; Maite Cutuli; Marta E García
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species.

Authors:  Takashi Sugita; Mami Tajima; Tomonobu Ito; Masuyoshi Saito; Ryoji Tsuboi; Akemi Nishikawa
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

3.  Agar Diffusion Procedures for Susceptibility Testing of Malassezia pachydermatis: Evaluation of Mueller-Hinton Agar Plus 2 % Glucose and 0.5 µg/ml Methylene Blue as the Test Medium.

Authors:  M Pasquetti; E Chiavassa; P Tizzani; P Danesi; A Peano
Journal:  Mycopathologia       Date:  2015-07-03       Impact factor: 2.574

4.  A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.

Authors:  S Rincón; M C Cepero de García; A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Efficacy of albaconazole against Candida albicans in a vaginitis model.

Authors:  Gloria M González; Efrén Robledo; Elvira Garza-González; Mariana Elizondo; J Gerardo González
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

6.  Keratitis caused by a rare fungus, Malassezia restricta.

Authors:  Takashi Suzuki; Nobuhide Hori; Tomoko Miyake; Yukiko Hori; Kiyofumi Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

7.  CLSI broth microdilution method for testing susceptibility of Malassezia pachydermatis to thiabendazole.

Authors:  Patrícia da Silva Nascente; Ana Raquel Mano Meinerz; Renata Osório de Faria; Luiz Filipe Damé Schuch; Mário Carlos Araújo Meireles; João Roberto Braga de Mello
Journal:  Braz J Microbiol       Date:  2009-06-01       Impact factor: 2.476

8.  Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.

Authors:  Aristea Velegraki; Evangelos C Alexopoulos; Stavroula Kritikou; George Gaitanis
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation.

Authors:  Koen van Rossem; Jenny A Lowe
Journal:  Clin Pharmacol       Date:  2013-01-30

10.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.